Skip to main content
Top
Published in: Inflammation 5/2018

01-10-2018 | ORIGINAL ARTICLE

Anti-Inflammatory Effects of Taraxasterol on LPS-Stimulated Human Umbilical Vein Endothelial Cells

Authors: Feng Zheng, Xiaomeng Dong, Xiangzhu Meng

Published in: Inflammation | Issue 5/2018

Login to get access

Abstract

In the present study, we used the human umbilical vein endothelial cells (HUVECs) to investigate the anti-inflammatory effects and mechanism of taraxasterol on vascular inflammation. HUVECs were pre-treated with taraxasterol 1 h before lipopolysaccharide (LPS) treatment. The concentrations of TNF-α, IL-8, PGE2, and NO were measured. The expression of VCAM-1, ICAM-1, iNOS, COX-2, NF-κB, and LXRα was detected by western blot analysis. The results showed that taraxasterol not only reduced the production of TNF-α, IL-8, PGE2, and NO induced by LPS, but also reduced the expression of iNOS and COX-2. Taraxasterol also suppressed LPS-induced NF-κB activation and VCAM-1 and ICAM-1 expression. Furthermore, taraxasterol concentration-dependently increased the expression of LXRα. The inhibition of taraxasterol on TNF-α, IL-8, PGE2, and NO production can be reversed by geranylgeranyl diphosphate (GGPP, the LXRα inhibitor). Here, we found that taraxasterol inhibited vascular inflammation through activating LXRα.
Literature
1.
go back to reference Ryan, S., C.T. Taylor, and W.T. McNicholas. 2009. Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Thorax 64: 631–636.PubMed Ryan, S., C.T. Taylor, and W.T. McNicholas. 2009. Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Thorax 64: 631–636.PubMed
2.
go back to reference Black, P.H., and L.D. Garbutt. 2002. Stress, inflammation and cardiovascular disease. Journal of Psychosomatic Research 52: 1–23.CrossRefPubMed Black, P.H., and L.D. Garbutt. 2002. Stress, inflammation and cardiovascular disease. Journal of Psychosomatic Research 52: 1–23.CrossRefPubMed
3.
go back to reference De Nardin, E. 2001. The role of inflammatory and immunological mediators in periodontitis and cardiovascular disease. Annals of Periodontology 6: 30–40.CrossRefPubMed De Nardin, E. 2001. The role of inflammatory and immunological mediators in periodontitis and cardiovascular disease. Annals of Periodontology 6: 30–40.CrossRefPubMed
4.
5.
go back to reference De Martin, R., M. Hoeth, R. Hofer-Warbinek, and J.A. Schmid. 2000. The transcription factor NF-kappa B and the regulation of vascular cell function. Arteriosclerosis, Thrombosis, and Vascular Biology 20: E83–E88.CrossRefPubMed De Martin, R., M. Hoeth, R. Hofer-Warbinek, and J.A. Schmid. 2000. The transcription factor NF-kappa B and the regulation of vascular cell function. Arteriosclerosis, Thrombosis, and Vascular Biology 20: E83–E88.CrossRefPubMed
6.
go back to reference Liu, J., H. Xiong, Y. Cheng, C. Cui, X. Zhang, L. Xu, and X. Zhang. 2013. Effects of taraxasterol on ovalbumin-induced allergic asthma in mice. Journal of Ethnopharmacology 148: 787–793.CrossRefPubMed Liu, J., H. Xiong, Y. Cheng, C. Cui, X. Zhang, L. Xu, and X. Zhang. 2013. Effects of taraxasterol on ovalbumin-induced allergic asthma in mice. Journal of Ethnopharmacology 148: 787–793.CrossRefPubMed
7.
go back to reference Zhang, X., H. Xiong, H. Li, and Y. Cheng. 2014. Protective effect of taraxasterol against LPS-induced endotoxic shock by modulating inflammatory responses in mice. Immunopharmacology and Immunotoxicology 36: 11–16.CrossRefPubMed Zhang, X., H. Xiong, H. Li, and Y. Cheng. 2014. Protective effect of taraxasterol against LPS-induced endotoxic shock by modulating inflammatory responses in mice. Immunopharmacology and Immunotoxicology 36: 11–16.CrossRefPubMed
8.
go back to reference Xiong, H., Y. Cheng, X. Zhang, and X. Zhang. 2014. Effects of taraxasterol on iNOS and COX-2 expression in LPS-induced RAW 264.7 macrophages. Journal of Ethnopharmacology 155: 753–757.CrossRefPubMed Xiong, H., Y. Cheng, X. Zhang, and X. Zhang. 2014. Effects of taraxasterol on iNOS and COX-2 expression in LPS-induced RAW 264.7 macrophages. Journal of Ethnopharmacology 155: 753–757.CrossRefPubMed
9.
go back to reference San, Z., Y. Fu, W. Li, E. Zhou, Y. Li, X. Song, T. Wang, Y. Tian, Z. Wei, M. Yao, Y. Cao, and N. Zhang. 2014. Protective effect of taraxasterol on acute lung injury induced by lipopolysaccharide in mice. International Immunopharmacology 19: 342–350.CrossRefPubMed San, Z., Y. Fu, W. Li, E. Zhou, Y. Li, X. Song, T. Wang, Y. Tian, Z. Wei, M. Yao, Y. Cao, and N. Zhang. 2014. Protective effect of taraxasterol on acute lung injury induced by lipopolysaccharide in mice. International Immunopharmacology 19: 342–350.CrossRefPubMed
10.
go back to reference Xueshibojie, L., Y. Duo, and W. Tiejun. 2016. Taraxasterol inhibits cigarette smoke-induced lung inflammation by inhibiting reactive oxygen species-induced TLR4 trafficking to lipid rafts. European Journal of Pharmacology 789: 301–307.CrossRefPubMed Xueshibojie, L., Y. Duo, and W. Tiejun. 2016. Taraxasterol inhibits cigarette smoke-induced lung inflammation by inhibiting reactive oxygen species-induced TLR4 trafficking to lipid rafts. European Journal of Pharmacology 789: 301–307.CrossRefPubMed
11.
go back to reference Wang, S., Y. Wang, X. Liu, L. Guan, L. Yu, and X. Zhang. 2016. Anti-inflammatory and anti-arthritic effects of taraxasterol on adjuvant-induced arthritis in rats. Journal of Ethnopharmacology 187: 42–48.CrossRefPubMed Wang, S., Y. Wang, X. Liu, L. Guan, L. Yu, and X. Zhang. 2016. Anti-inflammatory and anti-arthritic effects of taraxasterol on adjuvant-induced arthritis in rats. Journal of Ethnopharmacology 187: 42–48.CrossRefPubMed
12.
go back to reference Wang, J., C. Guo, Z. Wei, X. He, J. Kou, E. Zhou, Z. Yang, and Y. Fu. 2016. Morin suppresses inflammatory cytokine expression by downregulation of nuclear factor-kappaB and mitogen-activated protein kinase (MAPK) signaling pathways in lipopolysaccharide-stimulated primary bovine mammary epithelial cells. Journal of Dairy Science 99: 3016–3022.CrossRefPubMed Wang, J., C. Guo, Z. Wei, X. He, J. Kou, E. Zhou, Z. Yang, and Y. Fu. 2016. Morin suppresses inflammatory cytokine expression by downregulation of nuclear factor-kappaB and mitogen-activated protein kinase (MAPK) signaling pathways in lipopolysaccharide-stimulated primary bovine mammary epithelial cells. Journal of Dairy Science 99: 3016–3022.CrossRefPubMed
13.
go back to reference Boyle, E.M., Jr., S.T. Lille, E. Allaire, A.W. Clowes, and E.D. Verrier. 1997. Endothelial cell injury in cardiovascular surgery: atherosclerosis. The Annals of Thoracic Surgery 63: 885–894.CrossRefPubMed Boyle, E.M., Jr., S.T. Lille, E. Allaire, A.W. Clowes, and E.D. Verrier. 1997. Endothelial cell injury in cardiovascular surgery: atherosclerosis. The Annals of Thoracic Surgery 63: 885–894.CrossRefPubMed
14.
go back to reference Ridker, P.M., M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens. 1997. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. The New England Journal of Medicine 336: 973–979.CrossRefPubMed Ridker, P.M., M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens. 1997. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. The New England Journal of Medicine 336: 973–979.CrossRefPubMed
15.
go back to reference Berg, A.H., and P.E. Scherer. 2005. Adipose tissue, inflammation, and cardiovascular disease. Circulation Research 96: 939–949.CrossRefPubMed Berg, A.H., and P.E. Scherer. 2005. Adipose tissue, inflammation, and cardiovascular disease. Circulation Research 96: 939–949.CrossRefPubMed
16.
go back to reference Boyle, E.M., Jr., T.H. Pohlman, M.C. Johnson, and E.D. Verrier. 1997. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. The Annals of Thoracic Surgery 63: 277–284.CrossRefPubMed Boyle, E.M., Jr., T.H. Pohlman, M.C. Johnson, and E.D. Verrier. 1997. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. The Annals of Thoracic Surgery 63: 277–284.CrossRefPubMed
17.
go back to reference Tontonoz, P., and D.J. Mangelsdorf. 2003. Liver X receptor signaling pathways in cardiovascular disease. Molecular Endocrinology 17: 985–993.CrossRefPubMed Tontonoz, P., and D.J. Mangelsdorf. 2003. Liver X receptor signaling pathways in cardiovascular disease. Molecular Endocrinology 17: 985–993.CrossRefPubMed
18.
go back to reference Bruemmer, D., and R.E. Law. 2005. Liver x receptors: potential novel targets in cardiovascular diseases. Current Drug Targets. Cardiovascular & Haematological Disorders 5: 533–540.CrossRef Bruemmer, D., and R.E. Law. 2005. Liver x receptors: potential novel targets in cardiovascular diseases. Current Drug Targets. Cardiovascular & Haematological Disorders 5: 533–540.CrossRef
19.
go back to reference Wu, S., R. Yin, R. Ernest, Y. Li, O. Zhelyabovska, J. Luo, Y. Yang, and Q. Yang. 2009. Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. Cardiovascular Research 84: 119–126.CrossRefPubMedPubMedCentral Wu, S., R. Yin, R. Ernest, Y. Li, O. Zhelyabovska, J. Luo, Y. Yang, and Q. Yang. 2009. Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. Cardiovascular Research 84: 119–126.CrossRefPubMedPubMedCentral
20.
go back to reference Bradley, M.N., C. Hong, M. Chen, S.B. Joseph, D.C. Wilpitz, X. Wang, A.J. Lusis, A. Collins, W.A. Hseuh, J.L. Collins, R.K. Tangirala, and P. Tontonoz. 2007. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. The Journal of Clinical Investigation 117: 2337–2346.CrossRefPubMedPubMedCentral Bradley, M.N., C. Hong, M. Chen, S.B. Joseph, D.C. Wilpitz, X. Wang, A.J. Lusis, A. Collins, W.A. Hseuh, J.L. Collins, R.K. Tangirala, and P. Tontonoz. 2007. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. The Journal of Clinical Investigation 117: 2337–2346.CrossRefPubMedPubMedCentral
21.
go back to reference Hasani-Ranjbar, S., B. Larijani, and M. Abdollahi. 2009. A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflammation & Allergy Drug Targets 8: 2–10.CrossRef Hasani-Ranjbar, S., B. Larijani, and M. Abdollahi. 2009. A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflammation & Allergy Drug Targets 8: 2–10.CrossRef
22.
go back to reference Fu, Y., Z. Wei, E. Zhou, N. Zhang, and Z. Yang. 2014. Cyanidin-3-O-beta-glucoside inhibits lipopolysaccharide-induced inflammatory response in mouse mastitis model. Journal of Lipid Research 55: 1111–1119.CrossRefPubMedPubMedCentral Fu, Y., Z. Wei, E. Zhou, N. Zhang, and Z. Yang. 2014. Cyanidin-3-O-beta-glucoside inhibits lipopolysaccharide-induced inflammatory response in mouse mastitis model. Journal of Lipid Research 55: 1111–1119.CrossRefPubMedPubMedCentral
Metadata
Title
Anti-Inflammatory Effects of Taraxasterol on LPS-Stimulated Human Umbilical Vein Endothelial Cells
Authors
Feng Zheng
Xiaomeng Dong
Xiangzhu Meng
Publication date
01-10-2018
Publisher
Springer US
Published in
Inflammation / Issue 5/2018
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-018-0818-3

Other articles of this Issue 5/2018

Inflammation 5/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.